HELSINKI, Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses as measured by PET imaging in some patients. Results from the second part of trial, in which all patients will receive CDNF for an additional six months, are expected in Q3 2020.

https://www.prnewswire.com/news-releases/hera...10446.html

Europeans treat results release different than we do. I don't read this as a full throated positive result for CDNF but they are moving on and the market is pleased.